Eutravac (diphtheria-tetanus-acellular pertussis [DTaP] hepatitis B [HB] combined vaccine) / LG Chem - LARVOL DELTA

Deutravacitinib (dec) Long-Term Efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 poetyk pso study program (DDG-TAGUNG 2023) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Psoriasis

Deutravacitinib Impoves Dermatology Life Quality Index (DLQI) in Patients with moderates to Severe psoriasis: results from the phase 3 poetyk pso-1 and pso-2 trials (DDG-TAGUNG 2023) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Psoriasis

DeCravacitinib, An Oral, Selective Tyrosine Kinase 2 (TYK2) inhibitor, Compared to placebo and apremilast in moderate-to-sever plaque psoriasis: The Achievement of Absolute Pasi Thresholds in the phase 3 Studies poetyk pso-1 and pso-2 (FOBI 2022) - P3 | "Background: deutravacitinib is an oral, selective tyk2 inhibitor. in poetyk pso-1 and pso-2, patient with moderate-to-sever psoriasis treated with decravacitinib achieved clinically meaningful absolute pasi scores superior to placebo and apremilast."

Clinical • P3 data • Dermatology • Immunology • Psoriasis • TYK2

DeCravacitinib, An Oral, Selective Tyrosine Kinase 2 (TYK2) inhibitor, Compared to placebo and apremilast in moderate-to-sever plaque psoriasis: The Achievement of Absolute Pasi Thresholds in the phase 3 Studies poetyk pso-1 and pso-2 - P3 | "Background: deutravacitinib is an oral, selective tyk2 inhibitor. in poetyk pso-1 and pso-2, patient with moderate-to-sever psoriasis treated with decravacitinib achieved clinically meaningful absolute pasi scores superior to placebo and apremilast."

Clinical • P3 data • Dermatology • Immunology • Psoriasis • TYK2

DeCravacitinib, An Oral, Selective Tyrosine Kinase 2 (TYK2) inhibitor, Compared to placebo and apremilast in moderate-to-sever plaque psoriasis: The Achievement of Absolute Pasi Thresholds in the phase 3 Studies poetyk pso-1 and pso-2 - P3 | "Background: deutravacitinib is an oral, selective tyk2 inhibitor. in poetyk pso-1 and pso-2, patient with moderate-to-sever psoriasis treated with decravacitinib achieved clinically meaningful absolute pasi scores superior to placebo and apremilast."

Clinical • P3 data • Dermatology • Immunology • Psoriasis • TYK2

DeCravacitinib, An Oral, Selective Tyrosine Kinase 2 (TYK2) inhibitor, Compared to placebo and apremilast in moderate-to-sever plaque psoriasis: The Achievement of Absolute Pasi Thresholds in the phase 3 Studies poetyk pso-1 and pso-2 - P3 | "Background: deutravacitinib is an oral, selective tyk2 inhibitor. in poetyk pso-1 and pso-2, patient with moderate-to-sever psoriasis treated with decravacitinib achieved clinically meaningful absolute pasi scores superior to placebo and apremilast."

Clinical • P3 data • Dermatology • Immunology • Psoriasis • TYK2